Menopause hormone testing — when it helps and when it doesn't

The terminology, briefly

A few terms worth being clear about:

• Menopause. Defined as 12 consecutive months without a period (in absence of other cause). The average age in the UK is 51.
• Perimenopause. The transition phase leading up to menopause, often lasting 4–8 years. Hormones fluctuate; periods become irregular; classic symptoms emerge.
• Postmenopause. The years after menopause.
• Early menopause. Menopause occurring between 40 and 45.
• Premature ovarian insufficiency (POI). Loss of ovarian function before 40. Affects around 1% of women.
• Surgical / iatrogenic menopause. Caused by oophorectomy, certain cancer treatments, or some medications.

The NICE position on testing

NICE NG23 (the UK menopause guideline) is clear about hormone testing:

• Women over 45 with typical symptoms. Diagnose based on symptoms and pattern. Blood tests not routinely needed.
• Women 40–45 with menopause-like symptoms. Consider FSH testing if diagnosis uncertain.
• Women under 40 with menopause-like symptoms. Investigate for POI — typically two FSH measurements 4–6 weeks apart, alongside oestradiol.
• Women on HRT. Routine monitoring with hormone testing not generally needed; clinical response is the main guide.
• To confirm postmenopausal status. Specific scenarios (e.g. before stopping contraception) where blood tests have a role.

The reasoning: perimenopausal hormone levels fluctuate widely. A single FSH 'in normal range' doesn't rule out perimenopause; a single FSH 'menopausal' doesn't reliably confirm permanent ovarian decline. Symptoms are usually more informative.

Where private testing genuinely adds value

• Women under 40–45. Investigating POI or early menopause. The diagnosis matters because treatment recommendations and long-term health implications are different.
• Atypical presentations. When symptoms are unusual or could indicate thyroid, anaemia, depression, or other conditions — a wider panel (TSH, FSH, oestradiol, iron, vitamin D) sometimes clarifies.
• Women with prior gynaecological surgery where assessing ovarian status post-procedure matters.
• Pre-pregnancy planning where ovarian reserve (AMH) is relevant.
• Women considering HRT who want baseline data and a structured pre-prescription review.
• Women on HRT where the question is whether the dose / form is right for symptoms.
• Reassurance before major decisions (relocation, career, fertility) where understanding current ovarian status helps.

The main hormones

FSH (follicle stimulating hormone). Pituitary hormone that stimulates ovarian follicle development. As ovaries become less responsive (approaching menopause), the pituitary 'shouts louder' — FSH rises. Levels >30 IU/L on two measurements, with low oestradiol, are typically interpreted as menopausal range.

LH (luteinising hormone). Also rises as ovarian function declines. Usually trends with FSH.

Oestradiol (E2). The main ovarian oestrogen. Falls as menopause approaches and is consistently low postmenopause. Reference ranges vary by cycle day in premenopausal women, which is why timing matters.

AMH (anti-Müllerian hormone). Produced by small ovarian follicles, reflecting ovarian reserve. Falls steadily with age, becoming very low or undetectable as menopause approaches. AMH is more useful for fertility assessment than for confirming menopause per se.

Progesterone. Produced after ovulation. A blood progesterone test on day 21 of a 28-day cycle confirms ovulation has occurred. Drops sharply at menopause.

Testosterone. Also produced by ovaries (in smaller amounts than oestrogen). May contribute to symptoms (energy, libido, muscle strength) in menopause; some women benefit from testosterone replacement.

Prolactin. Tested if hyperprolactinaemia is suspected (raised prolactin can suppress ovulation and mimic menopausal symptoms).

TSH (thyroid). Often tested alongside menopause panel because thyroid dysfunction overlaps in symptoms (fatigue, mood, weight changes). See thyroid testing guide.

Timing considerations

For premenopausal women still cycling:

• FSH and LH are best tested in the early follicular phase (days 2–5 of cycle).
• Oestradiol cycle-day matters too.
• Progesterone is tested mid-luteal (around day 21 in a 28-day cycle, or 7 days before expected period).

For women with irregular cycles or no cycles, timing is less constrained — testing can be done at any point. Some clinicians repeat in 4–6 weeks for confirmation.

If you're on hormonal contraception (combined pill, hormonal IUS in some scenarios), FSH and oestradiol interpretation is affected — the panel may not give meaningful menopause information without a contraception pause, which isn't always practical.

POI — the diagnosis that matters most for younger women

Premature ovarian insufficiency (loss of ovarian function before 40) affects about 1% of women. It's significant because:

• Symptoms (irregular/absent periods, hot flushes, mood changes, vaginal dryness) often emerge years before the woman expects 'menopause'.
• Long-term health implications are real — increased cardiovascular risk, bone density loss — because the body is missing oestrogen at an age where it shouldn't be.
• HRT is usually recommended until at least the natural menopause age (~51) for symptom control and long-term health protection.
• Fertility implications: ovarian reserve is depleted, but spontaneous conception still occurs in a small minority of POI cases. Fertility planning and contraception both need consideration.

Diagnosis: typically two FSH measurements 4–6 weeks apart showing levels >25–30 IU/L, with low oestradiol, plus clinical context.

Perimenopause — the complicated middle

The 4–8 years before menopause are the hardest to pin down with blood tests. Hormones fluctuate dramatically — a woman can have normal premenopausal-range FSH one month and menopausal-range FSH the next. This is why NICE de-emphasises testing in this group and emphasises symptoms.

Common perimenopausal symptoms:

• Cycle changes (shorter, longer, heavier, lighter, skipped).
• Hot flushes and night sweats.
• Mood changes (anxiety, low mood, irritability, weepiness).
• Sleep disturbance.
• Brain fog, memory changes.
• Joint aches.
• Reduced libido.
• Vaginal dryness.
• Skin and hair changes.
• Weight changes (often gain, especially abdominal).

HRT (where appropriate) and lifestyle interventions can substantially improve symptoms. Decision to test or not test doesn't change the symptom management.

HRT context, briefly

This guide is about testing, not HRT. But a few HRT-relevant points:

• HRT is typically initiated based on symptoms, not test results.
• Type of HRT (oral vs transdermal, oestrogen alone vs combined, sequential vs continuous) depends on uterus status, age, cardiovascular risk, and preference.
• Testosterone in HRT — for some women, particularly with persistent libido or energy issues — increasingly considered but currently off-label in many UK contexts.
• Ongoing monitoring is mostly clinical; routine hormone testing on HRT isn't standard.
• For more detailed HRT discussion, your GP or a menopause specialist is the right route.

What to test — panel options

For most menopause-related questions, a reasonable panel:

• FSH, LH, oestradiol.
• TSH and free T4 (to exclude thyroid).
• Ferritin (to exclude iron deficiency contribution to fatigue).
• Vitamin D (often co-low).
• Optional: AMH (for ovarian reserve, relevant in fertility-context conversations).
• Optional: testosterone and SHBG (relevant for energy/libido conversations).
• Optional: full blood count, lipid panel, HbA1c (for cardiovascular baseline alongside HRT considerations).

How this fits with other testing

Menopause-related testing often pairs with thyroid testing, iron testing, and vitamin D testing because the symptom overlap is significant and excluding correctable contributors matters. For the broader blood testing picture see our private blood test guide.

If results are abnormal

Your pharmacist will annotate with context. Common pathways:

• POI-pattern results in women under 40. Urgent GP referral for full assessment and likely HRT initiation.
• Early menopause pattern (40–45). GP discussion, often HRT.
• Perimenopause pattern. Often confirms what symptoms already suggest. HRT discussion based on symptoms and preferences.
• Atypical patterns. Specialist referral as appropriate.
• Other markers abnormal alongside. Address the correctable contributors first — sometimes 'menopause symptoms' partly resolve with iron and thyroid optimisation.

The Leicester clinic context

We process menopause panels through UKAS-accredited labs with 24–48 hour turnaround. Pharmacist-reviewed results with annotated recommendations. Free summary letter to your GP if HRT initiation or further investigation is indicated.

The next step

If you're under 45 with menopause-like symptoms, want to investigate ovarian reserve, or want a structured baseline before discussing HRT with your GP, booking a same-day phlebotomy is straightforward. For broader symptom workups, the test often pairs with thyroid and iron.